TOI Relative Valuation
TOI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TOI is overvalued; if below, it's undervalued.
Historical Valuation
Oncology Institute Inc (TOI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.18. The fair price of Oncology Institute Inc (TOI) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：3.25
Fair
-9.23
PE
1Y
3Y
5Y
Trailing
Forward
7636.30
EV/EBITDA
Oncology Institute Inc. (TOI) has a current EV/EBITDA of 7636.30. The 5-year average EV/EBITDA is 204.25. The thresholds are as follows: Strongly Undervalued below -2634.04, Undervalued between -2634.04 and -1214.90, Fairly Valued between 1623.39 and -1214.90, Overvalued between 1623.39 and 3042.54, and Strongly Overvalued above 3042.54. The current Forward EV/EBITDA of 7636.30 falls within the Strongly Overvalued range.
-18.52
EV/EBIT
Oncology Institute Inc. (TOI) has a current EV/EBIT of -18.52. The 5-year average EV/EBIT is -7.06. The thresholds are as follows: Strongly Undervalued below -24.25, Undervalued between -24.25 and -15.66, Fairly Valued between 1.53 and -15.66, Overvalued between 1.53 and 10.13, and Strongly Overvalued above 10.13. The current Forward EV/EBIT of -18.52 falls within the Undervalued range.
0.51
PS
Oncology Institute Inc. (TOI) has a current PS of 0.51. The 5-year average PS is 0.49. The thresholds are as follows: Strongly Undervalued below -0.85, Undervalued between -0.85 and -0.18, Fairly Valued between 1.17 and -0.18, Overvalued between 1.17 and 1.84, and Strongly Overvalued above 1.84. The current Forward PS of 0.51 falls within the Historic Trend Line -Fairly Valued range.
-45.10
P/OCF
Oncology Institute Inc. (TOI) has a current P/OCF of -45.10. The 5-year average P/OCF is -7.64. The thresholds are as follows: Strongly Undervalued below -33.38, Undervalued between -33.38 and -20.51, Fairly Valued between 5.22 and -20.51, Overvalued between 5.22 and 18.09, and Strongly Overvalued above 18.09. The current Forward P/OCF of -45.10 falls within the Strongly Undervalued range.
-135.62
P/FCF
Oncology Institute Inc. (TOI) has a current P/FCF of -135.62. The 5-year average P/FCF is -7.50. The thresholds are as follows: Strongly Undervalued below -59.62, Undervalued between -59.62 and -33.56, Fairly Valued between 18.55 and -33.56, Overvalued between 18.55 and 44.61, and Strongly Overvalued above 44.61. The current Forward P/FCF of -135.62 falls within the Strongly Undervalued range.
Oncology Institute Inc (TOI) has a current Price-to-Book (P/B) ratio of -24.40. Compared to its 3-year average P/B ratio of 0.49 , the current P/B ratio is approximately -5107.67% higher. Relative to its 5-year average P/B ratio of 0.99, the current P/B ratio is about -2563.91% higher. Oncology Institute Inc (TOI) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -84.78%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -66.10% , the current FCF yield is about -100.00% lower.
-25.68
P/B
Median3y
0.49
Median5y
0.99
-9.11
FCF Yield
Median3y
-84.78
Median5y
-66.10
Competitors Valuation Multiple
The average P/S ratio for TOI's competitors is , providing a benchmark for relative valuation. Oncology Institute Inc Corp (TOI) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 36.70%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TOI increased by 945.31% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.49 to -5.06.
The secondary factor is the Revenue Growth, contributed 36.70%to the performance.
Overall, the performance of TOI in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Oncology Institute Inc (TOI) currently overvalued or undervalued?
What is Oncology Institute Inc (TOI) fair value?
How does TOI's valuation metrics compare to the industry average?
What is the current P/B ratio for Oncology Institute Inc (TOI) as of Dec 05 2025?
What is the current FCF Yield for Oncology Institute Inc (TOI) as of Dec 05 2025?
What is the current Forward P/E ratio for Oncology Institute Inc (TOI) as of Dec 05 2025?